Activin and Inhibin

BAY-850 is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC 50 of 166 nM.In VitroBAY-850 competes with the binding of a mono-acetylated Histone H4 N-terminal peptide to ATAD2 BD with an IC 50

BAY-850 is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC 50 of 166 nM.In VitroBAY-850 competes with the binding of a mono-acetylated Histone H4 N-terminal peptide to ATAD2 BD with an IC 50

BAY-899 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC 50 s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively. BAY-899 can reduce sex hormone levelsIn VivoBAY-899 (oral: 12.5 mg/kg/day:

BAY-899 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC 50 s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively. BAY-899 can reduce sex hormone levelsIn VivoBAY-899 (oral: 12.5 mg/kg/day:

BAY-899 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC 50 s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively. BAY-899 can reduce sex hormone levelsIn VivoBAY-899 (oral: 12.5 mg/kg/day:

BAY-899 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC 50 s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively. BAY-899 can reduce sex hormone levelsIn VivoBAY-899 (oral: 12.5 mg/kg/day:

BAY-899 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC 50 s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively. BAY-899 can reduce sex hormone levelsIn VivoBAY-899 (oral: 12.5 mg/kg/day:

BAY-899 is an orally active and selective luteinizing hormone receptor (LH-R) antagonist with IC 50 s of 185 nM and 46nM for hLH (human LH) and rLH (rat LH), respectively. BAY-899 can reduce sex hormone levelsIn VivoBAY-899 (oral: 12.5 mg/kg/day:

BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a K D value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A ,

BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a K D value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A ,

BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a K D value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A ,

BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a K D value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A ,